Key Capital Management’s Oruka Therapeutics ORKA Stock Holding History

Key Capital Management’s Portfolio ORKA Stock Details ORKA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.25K	Buy	+24	New	+$1.6K	﹤0.01%	562

Other funds holding ORKA

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

SAM

Synergy Asset Management Vancouver, Washington $1.06B AUM 36.26% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

SAM

SEB Asset Management Stockholm $26.6B AUM

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Key Capital Management's ORKA Position: Q2 2026 in Review

Key Capital Management opened a new position in Oruka Therapeutics (ORKA) in Q2 2026: 24 shares worth $2.25K. The stake represents ﹤0.01% of the portfolio and ranks #562 among its holdings.

62 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

Key Capital Management held 24 shares of Oruka Therapeutics worth $2.25K as of Q2 2026.
Oruka Therapeutics was a new Key Capital Management position in Q2 2026.
Oruka Therapeutics made up ﹤0.01% of Key Capital Management's portfolio in Q2 2026, its #562 holding.
62 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on Key Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.